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Caroli’s disease (CD) is a rare autosomal recessive disorder characterized by intrahepatic cystic dilatation of the bile ducts. Patients
with bilobar or progressive disease may require orthotopic liver transplantation (OLT). In the MELD era, living donor liver
transplantation (LDLT) raised as the ultimate treatment option for these patients, once their MELD score is usually low. Herein,
we describe 2 cases of patients (a 2-year-old girl and a 19-year-old teenager) that successfully underwent LDLT as a treatment for
diﬀuseCD.ThegoodpostoperativecoursesofthetwocasesindicatethatLDLTisafeasibleoptioninthetreatmentofthisdisorder,
even in complicated or early age patients.
1.Introduction
Caroli’s disease (CD) is a rare autosomal recessive disorder
characterized by intrahepatic cystic dilatation of the bile
ducts. It was ﬁrst described in 1906 [1] and named after
Caroli in 1958 [2]. It is considered type V of Todani’s
classiﬁcation for bile duct cysts [3]. Clinical progression
and presentation of patients with CD is heterogeneous as
long as symptoms may be absent for years or may occur
at a very early age. When progressive, it leads to recurrent
cholangitis, jaundice, right upper quadrant abdominal pain,
intrahepatic stones accumulation, portal hypertension, and
liver failure [4]. When combined with congenital hepatic
ﬁbrosis,itisknownasCaroli’ssyndrome(CS)orGrumbach’s
disease. In this case, portal hypertension and hepatic ﬁbrosis
are responsible for the clinical manifestations. Many renal
disorders have been described in association with these
diseases, including autosomal recessive polycystic kidney
disease [5].
Additionally,CDposesanotherlife-threateningproblem:
it has a relatively high incidence of intrahepatic malignant
tumors. Some authors have found cholangiocellular carci-
noma (CCC) in 7% to 25% of patients, suggesting that the
riskofmalignanttumorsdevelopingis100timesgreaterthan
that of the general population [6, 7].
Patients with bilobar disease with recurrent cholangi-
tis or complications related to portal hypertension may
require orthotopic liver transplantation (OLT). After the
MELD score implantation, living donor liver transplantation
(LDLT) raised as the ultimate treatment option for patients
with CD complicated by recurrent cholangitis or portal
hypertension, not amenable to conservative treatment. This
is explained by thelow scoreoftenachieved by thesepatients,
as other cholestatic diseases. Few case reports have described
experienceofOLTinpatientswithCD,especiallyinchildren.
CD is a rare indication forliver transplantation that accounts
for 0.13% of all liver transplants performed in the United
States [8]. Herein we describe 2 cases of patients that
underwent LDLT as a treatment for CD.
2.MaterialandMethods
Between March 2002 and January 2011, a total of 400 liver
transplants were performed at our liver transplantation unit.
Among these, 142 received graft from a living donor. Two
patients were transplanted due to diﬀuse CD. The diagnosis2 ISRN Surgery
Figure 1: Preoperatory magnetic resonance of patient 1, showing
the intrahepatic cystic dilatation of the bile ducts, especially on the
right liver.
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Figure 2: Preoperatory magnetic resonance of patient 2, reveling
diﬀuse cystic dilatation of the bile ducts.
was based on clinical presentation, magnetic resonance
image (Figures 1 and 2), and pathological ﬁndings.
Case 1. A 2-year-old girl, who was diagnosed with CD
associated to cirrhosis when she was 6 months old due to
symptomatic hepatomegaly. Her PELD score was 6. She was
submitted to an LDLT and received a left lobe graft from
her father. The graft weighted 240g and corresponded to
1.96% GRWR. Surgery recovering was uneventfully for both
patients. Donor and recipient were discharged on the 6th
and 21th postoperative day (POD), respectively. Immuno-
suppression was achieved using Methylprednisolone and
Tacrolimus. She is in good health after 82 months posttrans-
plantation.
Case 2. A 19-year-old girl, who was diagnosed with bilobar
CDwhenshewas13yearsold,afteranepisodeofcholangitis.
Her MELD score was 15. The poor quality of live caused by
many jaundice and cholangitis events led to transplantation.
She underwent an LDLT and received a right liver graft from
her father. The graft’s weight was 706g, corresponding to
1.21% GRWR. Liver specimen conﬁrmed intrahepatic cystic
Figure 3: Inspection of liver specimen of patient 2 conﬁrmed
intrahepatic bile ducts’ cystic dilatation.
dilatationofthebileducts(Figure 3).Donorhadanunevent-
ful recovery and was discharged on the 7th POD. At the 10th
POD, the recipient presented biliary complication, named
bile leak with infected collection, which was submitted to
percutaneous drainage and antibiotic treatment. No other
complication occurred. She was discharged on the 29th POD
and is well after 30 months of posttransplantation follow-up.
Postoperatively, Tacrolimus and Methylprednisolone were
prescribed as immunosuppressive agents.
In both cases, the recipient extrahepatic bile duct was
resected and hepaticojejunostomy was performed.
3. Discussion
CD is a rare congenital disorder characterized by multifocal
segmental and communicating saccular or cystic dilatations
of the intrahepatic bile ducts and is believed to be caused
by an incomplete and faulty remodeling of the embryonic
ductal plate [9]. There are two forms of the disease, one
associated with congenital hepatic ﬁbrosis, which is called
CS, and the other a simple form occurring alone. The
hereditary aspect of CD and CS is generally considered
autosomal recessive.
The disease prevalence is 1/1,000,000 of the popula-
tion, but with better image techniques, such as magnetic
resonance cholangiography, which oﬀer reliable pictures of
the biliary system, CD appears to be more prevalent than
previously reported [10].
Management of patients with CD or CS is still conﬂicted,
because time and severity of onset can vary a lot. The
long-term prognosis for these patients is poor, especially
when recurrent cholangitis or extensive bilobar disease is
present. Tsuchida et al. reviewed 50 cases reported since
1968 and identiﬁed 46% of mortality, primarily as a
result of septicemia, liver abscesses, liver failure, and portal
hypertension [11]. For patients with diﬀuse manifestations
of CD, combined approaches with partial hepatectomy and
biliodigestive anastomosis were not able to prevail. Even
though extended resections may be suitable for a few
patients, total replacement of the liver has been consideredISRN Surgery 3
Table 1: Liver transplantation for Caroli’s Disease information researched on MEDLINE Database.
Author Year N DDLT LDLT Age (years) F/M Kidney Tx Suvival (1y-3y-5y) Followup (months)
Balsells [13] 1993 1 1 — 25 1F — 100%-NA-NA 24
Shiano [14] 1997 1 1 — 35 1F — 100%-NA-NA 21
Sans [15] 1997 2 2 — 41.5 (21–62) 1F/1M — NA-NA-NA 36 (8–64)
Marx [16] 1999 1 1 — 24 F — NA-NA-NA 3
Waechter [17] 2001 2 2 — 36.5 (32–41) 2M — NA NA
Takatsuki [18] 2001 1 — 1 36 1F — 100%-NA-NA 29
Ammori [19] 2002 5 5 — NA NA 1/5 80%-NA-NA 20 (15–32)
Ninan [20] 2002 1 1 — 25 1F — 100%-100%-NA 48
Madjov [21] 2005 1 1 — 25 1M — NA-NA-NA NA
Kassahun [10] 2005 2 2 — NA 2F — 100%-100%-NA 48
Dalgic [22] 2005 1 — 1 NA NA — NA-NA-NA NA
De Kerckhove [23] 2006 3 3 — 38.3 (11–68.1) 1F/2M 2/3 NA-NA-NA 98.6m (8–204)
Bockhorn [7] 2006 2 1 1 NA NA — 100%-NA-NA 31
Habib [12] 2006 30 30 — 25.5 15F/15M — 76%-NA-65% 91
Mabrut [24] 2007 5 5 — NA NA 2/5 NA-NA-NA NA
Liu [25] 2007 2 2 — NA NA — 100%-100%-0% 41.5 (36–47)
Millwala [8] 2008 104 100 4 35.1 57F/47M 8/104 86.3%-78.4%-77% NA
Amezaga [26] 2008 1 1 — 45 NA — NA-NA-NA NA
Wang [27] 2008 3 3 — 15.3 (12–33) 2F/1M — 100%-66%-NA 54.7 (34–82)
Ulrich [9] 2008 4 4 — 42.7 (26–60) 2F/2M 1/4 100%-100%-100% 109 (70–148)
Meier [28] 2008 1 1 — 8.2 1F — 100%-100%-NA 57
Aguilar [29] 2008 1 1 — 44 1F — 100%-100%-100% 72
DDLT: deceased donor liver transplantation; LDLT: living donor liver transplantation; F/M: female/male; NA: not available.
to be a more eﬀective treatment [12]. Moreover, the high
incidence of CCC associated with CD is another relevant
issue. Dayton et al. presented 10 patients with CCC in CD
who had a median age of 52 years and a maximum survival
of 4 months, evidencing the threat of this complication [6].
On this scenario, liver transplantation emerged as a curative
option for these patients.
On a MEDLINE search, we identiﬁed 22 reports of liver
transplantation for CD or CS [7–10, 12–29]. Information
about the transplants (number, deceased donor or living
donor, and follow-up time) and recipients (age, and survival
for 1, 3, and 5 years) was reported on Table 1.
Ulrich et al. showed a 100% survival after a nine-year
followup for 4 patients submitted to OLT, from a deceased
donor (DD), due to CD or CS [9]. De Kerckhove et al.
presented data from the European Liver Transplantation
Registry and noticed that 89 from 110 patients that under-
went OLT to control CD or CS were still alive after a
median follow-up of 812 days [23]. The large single-center
report, analyzing 30 patients transplanted for CD or CS, was
publishedbyHabibetal.,fromPittsburgh.Overalllong-term
graft survival rates at 1, 5, and 10 years were 73%, 62%, and
53%, and patient survival rates were 76%, 65%, and 56%,
respectively, [12]. All patients had DD liver transplantation
(DDLT). On a review carried out by Millwala et al., 104
patients with CD were identiﬁed from the UNOS Standard
Transplant Analysis and Research ﬁles of liver transplant
recipients between 1987 and 2006. CD or CS corresponded
to 0.13% of all indications for OLT. LDLT was performed in
3.8% of these patients. The overall graft and patient survival
at 1, 3, and 5 years were 79.9%, 72.4%, and 72.4%, and
86.3%, 78.4%, and 77%, respectively, [8]. Data show that
liver transplantation for CD or CS is a secure procedure with
an encouraging long-term outcome. Results are comparable
to those who undergo OLT for other etiologies of chronic
liver disease [11, 14, 28, 29].
A total of 174 patients were submitted to OLT for CD or
CS,accordingtoMEDLINEsearch.DDLTwascarriedouton
167 patients (96%). Seven patients (4%) underwent LDLT.
Our two cases were submitted to LDLT, unlike the majority
of patients reported. It is important to notice that in areas
of the world where there is a crucial shortage of potential
liver grafts, as occurs in Brazil with 7.2 donors/million
habitants/year,[30]LDLT is the onlyoption forpatients with
complicated CD, especially because of the low MELD score
achievedbythem.Isolatedcasesshownolong-termoutcome4 ISRN Surgery
diﬀerencebetweenLDLTandDDLTasatreatmentforCDor
CS [7, 22].
4. Conclusion
We successfully performed LDLT for 2 patients with diﬀuse
Caroli’s disease. The good postoperative courses of the two
cases reported here indicate that LDLT is a feasible option
in the treatment of this disorder, even when complicated
by recurrent cholangitis or carried out in an early age
patient. LDLT may be the only alternative for patients with
complicated CD in regions with a lack of DD grafts.
Conﬂicts of Interest
The authors declared that, there are no conﬂict of interests.
References
[1] H.R.VachellandW.M.Stevens,“Caseofintrahepaticcalculi,”
British Medical Journal, vol. 1, pp. 434–436, 1906.
[2] J. Caroli, R. Soupault, J. Kossakowski, L. Plocker, and Parad-
owska, “Congenital polycystic dilation of the intrahepatic bile
ducts; attempt at classiﬁcation,” La Semaine des Hˆ opitaux, vol.
34, no. 8, pp. 488–495, 1958.
[3] T.Todani,Y.Watanabe,andM.Narusue,“Congenitalbileduct
cysts.Classiﬁcation,operativeprocedures,andreviewofthirty
seven cases including cancer arising from choledochal cyst,”
AmericanJournalofSurgery,vol.134,no.2,pp.263–269,1977.
[4] A. C. F. Taylor and K. R. Palmer, “Caroli’s disease,” European
Journal of Gastroenterology and Hepatology,v o l .1 0 ,n o .2 ,p p .
105–108, 1998.
[5] R. Grumbach, J. Bourillon, and J. P. Auvert, “Maladie ﬁbro-
kystique du foie avec hypertension portale chez l’enfant,” La
Semaine des Hˆ opitaux, vol. 74, p. 30, 1954.
[6] M. T. Dayton, W. P. Longmire, and R. K. Tompkins, “Caroli’s
disease: a premalignant condition?” American Journal of
Surgery, vol. 145, no. 1, pp. 41–48, 1983.
[7] M. Bockhorn, M. Malag´ o, H. Lang et al., “The role of surgery
inCaroli’sdisease,”JournaloftheAmericanCollegeofSurgeons,
vol. 202, no. 6, pp. 928–932, 2006.
[8] F. Millwala, D. L. Segev, and P. J. Thuluvath, “Caroli’s disease
and outcomes after liver transplantation,” Liver Transplanta-
tion, vol. 14, no. 1, pp. 11–17, 2008.
[9] F. Ulrich, J. Pratschke, A. Pascher et al., “Long-term outcome
of liver resection and transplantation for caroli disease and
syndrome,” Annals of Surgery, vol. 247, no. 2, pp. 357–364,
2008.
[10] W. T. Kassahun, T. Kahn, C. Wittekind et al., “Caroli’s disease:
liver resection and liver transplantation. Experience in 33
patients,” Surgery, vol. 138, no. 5, pp. 888–898, 2005.
[11] Y. Tsuchida, T. Sato, K. Sanjo et al., “Evaluation of long-
term results of Caroli’s disease: 21 years’ observation of a
family with autosomal dominant inheritance, and review of
the literature,” Hepato-Gastroenterology,v o l .4 2 ,n o .2 ,p p .
175–181, 1995.
[12] S. Habib, O. Shakil, O. F. Couto et al., “Caroli’s disease and
orthotopic liver transplantation,” Liver Transplantation, vol.
12, no. 3, pp. 416–421, 2006.
[13] J. Balsells, C. Margarit, E. Murio et al., “Adenocarcinoma in
Caroli’s disease treated by liver transplantation,” HPB Surgery,
vol. 7, no. 1, pp. 81–87, 1993.
[14] T. D. Schiano, M. I. Fiel, C. M. Miller, H. C. Bodenheimer
Jr., and A. D. Min, “Adult presentation of Caroli’s syndrome
treated with orthotopic liver transplantation,” American Jour-
nal of Gastroenterology, vol. 92, no. 10, pp. 1938–1940, 1997.
[15] M. Sans, A. Rimola, M. Navasa et al., “Liver transplantation
in patients with Caroli’s disease and recurrent cholangitis,”
Transplant International, vol. 10, no. 3, pp. 241–244, 1997.
[16] G. Marx, B. Nashan, M. Cobas Meyer et al., “Septic shock after
liver transplantation for Caroli’s disease: clinical improvement
after treatment with C1-esterase inhibitor,” Intensive Care
Medicine, vol. 25, no. 9, pp. 1017–1020, 1999.
[17] F. L. Waechter, J. A. Sampaio, R. D. Pinto et al., “The role of
liver transplantationinpatients withCaroli’sdisease,” Hepato-
Gastroenterology, vol. 48, no. 39, pp. 672–674, 2001.
[18] M.Takatsuki,S.Uemoto,Y.Inomataetal.,“Living-donorliver
transplantation for Caroli’s disease with intrahepatic adeno-
carcinoma,” Journal of Hepato-Biliary-Pancreatic Surgery, vol.
8, no. 3, pp. 284–286, 2001.
[19] B. J. Ammori, B. L. Jenkins, P. C. M. Lim, K. R. Prasad, S. G.
Pollard,andJ.P.A.Lodge,“Surgicalstrategyforcysticdiseases
of the liver in a western hepatobiliary center,” World Journal of
Surgery, vol. 26, no. 4, pp. 462–469, 2002.
[20] V. T. Ninan, M. R. N. Nampoory, K. V. Johny et al., “Caroli’s
disease of the liver in a renal transplant recipient,” Nephrology
Dialysis Transplantation, vol. 17, no. 6, pp. 1113–1115, 2002.
[21] R. Madjov, P. Chervenkov, V. Madjova, and B. Balev, “Caroli’s
disease. Report of 5 cases and review of literature,” Hepato-
Gastroenterology, vol. 52, no. 62, pp. 606–609, 2005.
[22] A. Dalgic, F. Ozcay, G. Arslan et al., “Living-related liver trans-
plantation in pediatric patients,” Transplantation Proceedings,
vol. 37, no. 7, pp. 3133–3136, 2005.
[23] L. De Kerckhove, M. De Meyer, C. Verbaandert et al.,
“The place of liver transplantation in Caroli’s disease and
syndrome,” Transplant International, vol. 19, no. 5, pp. 381–
388, 2006.
[24] J. Y. Mabrut, C. Partensky, D. Jaeck et al., “Congenital intra-
hepatic bile duct dilatation is a potentially curable disease:
long-term results of a multi-institutional study,” Annals of
Surgery, vol. 246, no. 2, pp. 236–245, 2007.
[25] Y. B. Liu, J. W. Wang, K. R. Devkota et al., “Congenital
choledochal cysts in adults: twenty-ﬁve-year experience,”
ChineseMedicalJournal,vol.120,no.16,pp.1404–1407, 2007.
[26] R. U. Amezaga, N. Ravent´ os, J. Fuentes, J. El´ ıas, V. Tejedo, and
R. U. Echebarr´ ıa, “Diagnosis and management of choledochal
cysts. A review of 10 new cases,” Revista Espanola de Enfer-
medades Digestivas, vol. 100, no. 2, pp. 71–75, 2008.
[ 2 7 ]Z .X .W a n g ,L .N .Y a n ,B .L i ,Y .Z e n g ,T .F .W e n ,a n d
W. T. Wang, “Orthotopic liver transplantation for patients
with Caroli’s disease,” Hepatobiliary and Pancreatic Diseases
International, vol. 7, no. 1, pp. 97–100, 2008.
[28] C. Meier, J. Deutscher, S. M¨ uller et al., “Successful liver
transplantation in a child with Caroli’s disease,” Pediatric
Transplantation, vol. 12, no. 4, pp. 483–486, 2008.
[29] L. T. Aguilar, L. S. Moreno, L. B. Pulido et al., “Liver
transplantation consequential to Caroli’s syndrome: a case
report,” Transplantation Proceedings, vol. 40, no. 9, pp. 3121–
3122, 2008.
[30] ABTO, “Registro Brasileiro de transplantes ano XIV no
2-Janeiro/Dezembro 2008,” Data by request, March 2009,
http://www.abto.org.br/.